Peptide record

TPDB91687

HAL-2/8 HAL-2 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity modified_plain modified
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91687
HAL-2/8 HAL-2
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
modified_plain
Yes
A 12-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GKWMSLLKHILK-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
12 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial and Antifungal Activity
Halictines and their analogs Activity
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 12±1 µM
Anticancer
12

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 15±3 µM
Anticancer
15

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

IC50
IC50 = 35±3 µM
Anticancer
35

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

IC50
IC50 > 40 µM
Anticancer
40 µM

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

IC50
IC50 = 34 µM
Anticancer
34 µM

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 6 Activity

Activity

Not tested
Anticancer

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012